Based on the Silence Therapeutics plc stock forecast from 0 analysts, the average analyst target price for Silence Therapeutics plc is not available over the next 12 months. Silence Therapeutics plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Silence Therapeutics plc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Silence Therapeutics plc’s stock price was USD 0.97. Silence Therapeutics plc’s stock price has changed by +0.00% over the past week, +2.11% over the past month and -86.14% over the last year.
No recent analyst target price found for Silence Therapeutics plc
No recent average analyst rating found for Silence Therapeutics plc
Company Overview Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. Read Less
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company...Read More
Frequently Asked Questions About Silence Therapeutics plc (SLNCF) Stock
Stock Target Advisor's fundamental analysis for Silence Therapeutics plc's stock is Slightly Bearish.
Unfortunately we do not have enough data on SLNCF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SLNCF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SLNCF's stock to indicate if its overvalued.
The last closing price of SLNCF's stock was USD 0.97.
The most recent market capitalization for SLNCF is USD 0.14B.
Unfortunately we do not have enough analyst data on SLNCF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Silence Therapeutics plc's stock.
As per our most recent records Silence Therapeutics plc has 116 Employees.
Silence Therapeutics plc's registered address is 72 Hammersmith Road, London, United Kingdom, W14 8TH.
You can get more information about it from Silence Therapeutics plc's website at https://www.silence-therapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Silence Therapeutics plc (SLNCF) Stock
Stock Target Advisor's fundamental analysis for Silence Therapeutics plc's stock is Slightly Bearish.
Unfortunately we do not have enough data on SLNCF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SLNCF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SLNCF's stock to indicate if its overvalued.
The last closing price of SLNCF's stock was USD 0.97.
The most recent market capitalization for SLNCF is USD 0.14B.
Unfortunately we do not have enough analyst data on SLNCF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Silence Therapeutics plc's stock.
As per our most recent records Silence Therapeutics plc has 116 Employees.
Silence Therapeutics plc's registered address is 72 Hammersmith Road, London, United Kingdom, W14 8TH.
You can get more information about it from Silence Therapeutics plc's website at https://www.silence-therapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SLNCF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
